New drug cocktail shows promise for recurrent ovarian cancer
NCT ID NCT07454018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if this approach can delay cancer progression. About 45 women aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-SENSITIVE OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to outsmart recurrent ovarian cancer
- New drug duo aims to outperform chemo in ovarian cancer
- Could your own immune cells fight ovarian cancer? tiny trial aims to find out
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- New hope for ovarian cancer: Rina-S faces off against chemo in major trial